Related Experiment Video
Updated: Jan 24, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and
Jessika Lobraico-Fernandez1, Salma Baksh2, Eric Nemec3
1Sacred Heart University Physician Assistant Studies, Fairfield, CT, USA.
Insights
In elderly patients with nonvalvular atrial fibrillation, apixaban and dabigatran significantly reduce major bleeding risk compared to warfarin. Rivaroxaban showed no significant difference in bleeding risk versus warfarin.
Area of Science:
- Cardiology
- Pharmacology
- Geriatrics
Background:
- Current guidelines recommend anticoagulation for atrial fibrillation but lack specific guidance for the elderly.
- Direct oral anticoagulants (DOACs) like dabigatran, rivaroxaban, and apixaban are alternatives to warfarin, with limited research on their bleeding risks in older adults.
Purpose of the Study:
- To systematically review and compare the bleeding risk of different DOACs in elderly patients with nonvalvular atrial fibrillation (NVAF).
Main Methods:
- A systematic review and meta-analysis of studies reporting major bleeding events requiring hospitalization.
- Included patients with NVAF, excluded those with severe renal failure.
- Hazard ratios and 95% confidence intervals were calculated using a random-effects model.
Main Results:
- Apixaban and dabigatran demonstrated statistically significant reductions in major bleeding risk compared to warfarin (40% and 21% respectively).
- Rivaroxaban did not show a statistically significant difference in bleeding risk compared to warfarin.
- Data for edoxaban was insufficient for inclusion in the meta-analysis.
Conclusions:
- Apixaban and dabigatran are associated with a significantly lower risk of major bleeding in elderly NVAF patients compared to warfarin.
- Further head-to-head trials are needed to definitively establish the comparative bleeding risks of all DOACs.
Introduction:
The 2014 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) guidelines recommend anticoagulation to reduce clot formation and the risk of thromboembolic events in patients with atrial fibrillation but does not specify guidelines for the elderly population. Direct oral anticoagulants (DOACs) are newer US FDA-approved alternatives to warfarin and include dabigatran, rivaroxaban, apixaban and edoxaban. The efficacy of DOACs is heavily researched, but few studies have evaluated their bleeding risk.
Objectives:
This systematic review and meta-analysis investigates which DOAC has the lowest bleeding risk in elderly patients with nonvalvular atrial fibrillation (NVAF).
Methods:
CINAHL and MEDLINE databases were searched using specific keywords, and 244 results were identified and screened. Inclusion criteria required a major bleeding event requiring hospitalization as an outcome and excluded patients with severe renal failure. Articles that met inclusion criteria were assessed for risk of bias using the Cochrane Tool to Assess Risk of Bias in Cohort Studies. Review Manager (version 5) was used to perform the random-effects model meta-analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. P < 0.05 was considered statistically significant.
Results:
Six articles met inclusion criteria and encompassed 446,042 patients in total. Apixaban and dabigatran had statistically significant risk reductions compared with warfarin, whereas rivaroxaban did not (HR 0.60 [95% CI 0.52-0.69], p < 0.00001; HR 0.79 [95% CI 0.70-0.90], p = 0.0005; HR 1.03 [95% CI 0.86-1.22], p = 0.77, respectively.) Data regarding edoxaban were limited and thus not included in the analysis.
Conclusion:
Apixaban and dabigatran have a significantly decreased major bleeding risk (40 and 21%, respectively) compared with warfarin. There was no statistical difference in bleeding risk between rivaroxaban and warfarin. Head-to-head prospective randomized controlled trials are required to assess the true bleeding risk of each DOAC.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Directing Effect of Substituents: meta-Directing Groups
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
Review and Preview
Percentiles are a type of fractile that partition data into...

